DIAGNOS (OTCMKTS:DGNOF – Get Free Report) and Fathom (NASDAQ:FTHM – Get Free Report) are both small-cap business services companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, analyst recommendations, earnings, institutional ownership and dividends.
Earnings and Valuation
This table compares DIAGNOS and Fathom”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| DIAGNOS | $80,000.00 | 391.83 | -$3.08 million | ($0.04) | -6.57 |
| Fathom | $335.18 million | 0.11 | -$21.58 million | ($0.81) | -1.41 |
Profitability
This table compares DIAGNOS and Fathom’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| DIAGNOS | -5,964.91% | N/A | -188.02% |
| Fathom | -4.70% | -45.99% | -24.74% |
Volatility and Risk
DIAGNOS has a beta of -0.03, indicating that its stock price is 103% less volatile than the S&P 500. Comparatively, Fathom has a beta of 1.76, indicating that its stock price is 76% more volatile than the S&P 500.
Institutional and Insider Ownership
55.5% of Fathom shares are owned by institutional investors. 16.4% of Fathom shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Analyst Ratings
This is a summary of recent ratings and recommmendations for DIAGNOS and Fathom, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| DIAGNOS | 0 | 0 | 0 | 0 | 0.00 |
| Fathom | 1 | 0 | 0 | 1 | 2.50 |
Fathom has a consensus price target of $2.50, suggesting a potential upside of 119.30%. Given Fathom’s stronger consensus rating and higher probable upside, analysts clearly believe Fathom is more favorable than DIAGNOS.
Summary
Fathom beats DIAGNOS on 10 of the 14 factors compared between the two stocks.
About DIAGNOS
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.
About Fathom
Fathom Holdings Inc. provides a real estate services platform that integrates residential brokerage, mortgage, title, and insurance services in the United States. It operates through three segments: Real Estate Brokerage, Mortgage, and Technology. The Real Estate Brokerage segment provides real estate brokerage services. The Mortgage segment offers residential loan origination and underwriting services. The Technology segment provides Software as a Service solutions and data mining for third party customers. It offers access to various properties for sale or lease through its FathomRealty.com website to buyers, sellers, landlords, and tenants; insurance agency services; and title services. In addition, the company provides intelliAgent, a real estate technology platform that offers a suite of brokerage and agent level tools, technology, business processes, business intelligence and reporting, and training; transaction, personnel, customer relationship, and accounting management for agent transactions; and reporting, social media marketing, and other marketing and marketing repository services, as well as marketplace for add-on services and third-party technology. Its brands include Fathom Realty, Dagley Insurance, Encompass Lending, intelliAgent, LiveBy, Real Results, Verus Title, and Cornerstone. The company was founded in 2010 and is headquartered in Cary, North Carolina.
Receive News & Ratings for DIAGNOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DIAGNOS and related companies with MarketBeat.com's FREE daily email newsletter.
